D-0098-2023 Class II Terminated
FDA drug recall D-0098-2023 was initiated by RemedyRepack Inc. on Dec 20, 2022 and is designated Class II. Reason for recall: Failed Impurities/Degradation specifications The recall status is terminated (terminated Mar 3, 2023). Affected quantity: 132 Cards of 30 = 3960 Tablets.
Recall Details
- Product Type
- Drugs
- Report Date
- Jan 18, 2023
- Initiation Date
- Dec 20, 2022
- Termination Date
- Mar 3, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 132 Cards of 30 = 3960 Tablets
Product Description
Rifampin Capsules, 300 mg, 30 count blister card, Rx only, Mfg: Lupin Pharma, Baltimore, MD 21202, original NDC 68180-0659-07, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, Repackaged NDC 70518-2404-00.
Reason for Recall
Failed Impurities/Degradation specifications
Distribution Pattern
Product was distributed to one account in PA.
Code Information
Lot #: J0599794-022322, exp. date 02/28/2023; J0621369-052622, exp. date 06/30/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0098-2023
- openFDA file date
- Oct 21, 2026
- Loaded by RegDataLab
- Oct 23, 2026